Focus on tumor microenvironment remodeling： advantages and considerations of traditional Chinese herbal medicines and their effective components in intervening tumor recurrence and metastasis

HAN Yicun; JI Qing

doi:10.16305/j.1007-1334.2023.2301033

您当前的位置：

首页 >

文章列表页 >

Focus on tumor microenvironment remodeling： advantages and considerations of traditional Chinese herbal medicines and their effective components in intervening tumor recurrence and metastasis

更新时间：2023-04-08

- Focus on tumor microenvironment remodeling： advantages and considerations of traditional Chinese herbal medicines and their effective components in intervening tumor recurrence and metastasis
- Shanghai Journal of Traditional Chinese Medicine Vol. 57, Issue 4, Pages: 1-7(2023)
- 作者机构：
  
  1.上海中医药大学附属曙光医院（上海 201203）
- 作者简介：
- 基金信息：
- DOI：10.16305/j.1007-1334.2023.2301033
  CLC：
扫描看全文
韩懿存,季青.聚焦肿瘤微环境重塑：中药及其有效成分干预肿瘤复发转移的优势与思考[J].上海中医药杂志,2023,57(4):1-7.

HAN Yicun,JI Qing.Focus on tumor microenvironment remodeling： advantages and considerations of traditional Chinese herbal medicines and their effective components in intervening tumor recurrence and metastasis[J].Shanghai Journal of Traditional Chinese Medicine,2023,57(4):1-7.
韩懿存,季青.聚焦肿瘤微环境重塑：中药及其有效成分干预肿瘤复发转移的优势与思考[J].上海中医药杂志,2023,57(4):1-7. DOI： 10.16305/j.1007-1334.2023.2301033.

HAN Yicun,JI Qing.Focus on tumor microenvironment remodeling： advantages and considerations of traditional Chinese herbal medicines and their effective components in intervening tumor recurrence and metastasis[J].Shanghai Journal of Traditional Chinese Medicine,2023,57(4):1-7. DOI： 10.16305/j.1007-1334.2023.2301033.

摘要

肿瘤微环境（TME）的形成直接介导了肿瘤进展和转移，加剧了癌症患者的死亡风险。靶向TME成为癌症患者治疗的关键。免疫检查点抑制剂（ICIs）临床获益明显，是通过重塑肿瘤免疫微环境抑制肿瘤转移的成功示例，但其面临着不良反应事件、耐药和多数癌症患者响应率不佳等难题。中医对肿瘤的治疗着眼于人的整体，中药具有多靶点、多组分、多方位作用的特点，可通过逆转免疫抑制、减轻炎症微环境、重塑TME代谢等方式干预肿瘤转移的全过程，在克服耐药、预防转移、提高患者生存质量、延长生命等诸多方面发挥了不可忽视的作用。

Abstract

The formation of the tumor microenvironment （TME） directly mediates tumor progression and metastasis， exacerbating the risk of death in cancer patients. Targeting TME has become the key to the treatment of cancer. The significant clinical benefit of immune checkpoint inhibitors （ICIs） is a successful example of tumor metastasis suppression by remodeling the TME， but there are still challenges such as adverse events， drug resistance， and poor response rates in most cancer patients. Traditional Chinese medicine deals with tumor treatment from a holistic perspective. With multi-target， multi-component and multi-directional effects， traditional Chinese herbal medicines （TCHMs） can intervene in the entire process of tumor metastasis by reversing immunosuppression， reducing the inflammatory microenvironment and remodeling TME metabolism， and TCHMs have played a non-negligible role in overcoming drug resistance， preventing metastasis， improving quality of survival and prolonging life， etc.

关键词

癌症肿瘤微环境中药复发转移作用机制

Keywords

cancertumor microenvironmenttraditional Chinese herbal medicinerecurrencemetastasismechanism of action

references

CHAFFER C L， WEINBERG R A. A perspective on cancer cell metastasis［J］. Science， 2011， 331（6024）： 1559-1564.

SUNG H， FERLAY J， SIEGEL R L， et al. Global Cancer Statistics 2020： GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin， 2021， 71（3）： 209-249.

LI H， ZHOU L， ZHOU J， et al. Underlying mechanisms and drug intervention strategies for the tumour microenvironment［J］. J Exp Clin Cancer Res， 2021， 40（1）： 97.

POSTOW M A， SIDLOW R， HELLMANN M D. Immune-related adverse events associated with immune checkpoint blockade［J］. N Engl J Med， 2018， 378（2）： 158-168.

LIU Y， CAO X. Characteristics and significance of the pre-metastatic niche［J］. Cancer Cell， 2016， 30（5）： 668-681.

KONG H， KIM S B. Exosomal communication between the tumor microenvironment and innate immunity and its therapeutic application［J］. Immune Netw， 2022， 22（5）： e38.

DEBERARDINIS R J. Tumor microenvironment， metabolism， and immunotherapy［J］. N Engl J Med， 2020， 382（9）： 869-871.

YOSHINO T， ARNOLD D， TANIGUCHI H， et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer： a JSMO-ESMO initiative endorsed by CSCO， KACO， MOS， SSO and TOS［J］. Ann Oncol， 2018， 29（1）： 44-70.

孙正魁，江泽飞. 2022版《中国临床肿瘤学会乳腺癌诊疗指南》更新解读［J］. 中国肿瘤外科杂志，2022， 14（3）： 212-218.

GROTHEY A， VAN CUTSEM E， SOBRERO A， et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer（CORRECT）： an international， multicentre， randomised， placebo-controlled， phase 3 trial［J］. Lancet， 2013， 381（9863）： 303-312.

ALIEVA M， VAN RHEENEN J， BROEKMAN M L D. Potential impact of invasive surgical procedures on primary tumor growth and metastasis［J］. Clin Exp Metastasis， 2018， 35（4）： 319-331.

YIN T， HE S， YE T， et al. Antiangiogenic therapy using sunitinib combined with rapamycin retards tumor growth but promotes metastasis［J］. Transl Oncol， 2014， 7（2）： 221-229.

WEISSHARDT P， TRARBACH T， DURIG J， et al. Tumor vessel stabilization and remodeling by anti-angiogenic therapy with bevacizumab［J］. Histochem Cell Biol， 2012， 137（3）： 391-401.

FAN F， SAMUEL S， GAUR P， et al. Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration［J］. Br J Cancer， 2011， 104（8）： 1270-1277.

SEZER A， KILICKAP S， GUMUŞ M， et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%： a multicentre， open-label， global， phase 3， randomised， controlled trial［J］. Lancet， 2021， 397（10274）： 592-604.

SYN N L， TENG M W L， MOK T S K， et al. De-novo and acquired resistance to immune checkpoint targeting［J］. Lancet Oncol， 2017， 18（12）： e731-e741.

LI Z， ZHANG G， CAO N， et al. Effects of traditional Chinese medicine collaborative model （TCMCM） combined with adjuvant chemotherapy on Ⅲb and Ⅲc gastric cancer： a protocol for a randomized controlled trial［J］. Trials， 2022， 23（1）： 68.

LI X， ZHU， X， REN J. Impact of Chinese herbal medicine on survival， relapse and metastasis in women with breast cancer： a systematic review of randomized controlled trial［J］. J Altern Complem Med， 2014， 20（5）： A62.

YEH M H， WU H C， LIN N W， et al. Long-term use of combined conventional medicine and Chinese herbal medicine decreases the mortality risk of patients with lung cancer［J］. Complement Ther Med， 2020， 52： 102427.

安君君. 培土生金汤联合化疗治疗肺脾气虚型中晚期非小细胞肺癌患者的临床研究［D］.郑州：河南中医药大学，2019.

杨妮，徐建良，鲁利碧，等. 中药联合免疫抑制剂及靶向药治疗晚期肝癌并肺多发转移患者1例［J］. 中西医结合肝病杂志，2022， 32（7）： 658-660.

张志涛. 自拟健脾除积方联合免疫检查点抑制剂治疗晚期非小细胞肺癌的临床观察［D］.承德：承德医学院，2022.

TIAN L， SHEN D， LI X， et al. Ginsenoside Rg3 inhibits epithelial-mesenchymal transition （EMT） and invasion of lung cancer by down-regulating FUT4［J］. Oncotarget， 2016， 7（2）： 1619-1632.

LI H， HUANG N， ZHU W， et al. Modulation the crosstalk between tumor-associated macrophages and non-small cell lung cancer to inhibit tumor migration and invasion by ginsenoside Rh2［J］. BMC Cancer， 2018， 18（1）： 579.

JIANG Z， QIAN J， DONG H， et al. The traditional Chinese medicine Achyranthes bidentata and our de novo conception of its metastatic chemoprevention： from phytochemistry to pharmacology［J］. Sci Rep， 2017， 7（1）： 3888.

XU T M， CUI M H， XIN Y， et al. Inhibitory effect of ginsenoside Rg3 on ovarian cancer metastasis［J］. Chin Med J （Engl）， 2008， 121（15）： 1394-1397.

JUNG Y Y， UM J Y， NARULA A S， et al. Identification of matrine as a novel regulator of the CXCR4 signaling axis in tumor cells［J］. Int J Mol Sci， 2020， 21（13）：4731.

HUANG M， XIN W. Matrine inhibiting pancreatic cells epithelial-mesenchymal transition and invasion through ROS/NF-κB/MMPs pathway［J］. Life Sci， 2018， 192： 55-61.

SU Y C， LIN I H， SIAO Y M， et al. Modulation of the tumor metastatic microenvironment and multiple signal pathways by Prunella vulgaris in human hepatocellular carcinoma［J］. Am J Chin Med， 2016， 44（4）： 835-849.

LUO W， LIU X， SUN W， et al. Toosendanin， a natural product， inhibited TGF-β1-induced epithelial-mesenchymal transition through ERK/Snail pathway［J］. Phytother Res， 2018， 32（10）： 2009-2020.

PEI Z， FU W， WANG G. A natural product toosendanin inhibits epithelial-mesenchymal transition and tumor growth in pancreatic cancer via deactivating Akt/mTOR signaling［J］. Biochem Biophys Res Commun， 2017， 493（1）： 455-460.

LIN H J， KAO S T， SIAO Y M， et al. The Chinese medicine Sini-San inhibits HBx-induced migration and invasiveness of human hepatocellular carcinoma cells［J］. BMC Complement Altern Med， 2015， 15： 348.

ZHANG Z， LIU J， LIU Y， et al. Virtual screening of the multi-gene regulatory molecular mechanism of Si-Wu-tang against non-triple-negative breast cancer based on network pharmacology combined with experimental validation［J］. J Ethnopharmacol， 2021， 269： 113696.

GUO Q， PEI X H， CHU A J， et al. The mechanism of action of Fangji Huangqi Decoction on epithelial-mesenchymal transition in breast cancer using high-throughput next-generation sequencing and network pharmacology［J］. J Ethnopharmacol， 2022， 284： 114793.

LIU X F， LI J W， CHEN H Z， et al. Yanghe Huayan decoction inhibits the capability of trans-endothelium and angiogenesis of HER2+ breast cancer via pAkt signaling［J］. Biosci Rep， 2019， 39（2）：BSR20181260.

XIE C F， FENG K L， WANG J N， et al. Jianpi Huayu decoction inhibits the epithelial-mesenchymal transition of hepatocellular carcinoma cells by suppressing exosomal miR-23a-3p/Smad signaling［J］. J Ethnopharmacol， 2022， 294： 115360.

SHIAU J Y， CHANG Y Q， NAKAGAWA-GOTO K， et al. Phytoagent deoxyelephantopin and its derivative inhibit triple negative breast cancer cell activity through ROS-mediated exosomal activity and protein functions［J］. Front Pharmacol， 2017， 8： 398.

WEI Y， LI M， CUI S， et al. Shikonin inhibits the proliferation of human breast cancer cells by reducing tumor-derived exosomes［J］. Molecules， 2016， 21（6）： 777.

GERNAPUDI R， YAO Y， ZHANG Y， et al. Targeting exosomes from preadipocytes inhibits preadipocyte to cancer stem cell signaling in early-stage breast cancer［J］. Breast Cancer Res Treat， 2015， 150（3）： 685-695.

何兰，曹如柔，杨晓，等. 健脾消癌方干预肠癌细胞外泌体对巨噬细胞TGF-β1/Smad信号通路的调控作用研究［J］. 中医药导报，2022， 28（11）： 30-35.

QUE Z J， YANG Y， LIU H T， et al. Jinfukang regulates integrin/Src pathway and anoikis mediating circulating lung cancer cells migration［J］. J Ethnopharmacol， 2021， 267： 113473.

QUE Z J， YAO J L， ZHOU Z Y， et al. Jinfukang inhibits lung cancer metastasis by upregulating CX3CL1 to recruit NK cells to kill CTCs［J］. J Ethnopharmacol， 2021， 275： 114175.

XIA J， MA S， ZHU X， et al. Versatile ginsenoside Rg3 liposomes inhibit tumor metastasis by capturing circulating tumor cells and destroying metastatic niches［J］. Sci Adv， 2022， 8（6）： eabj1262.

CELIA-TERRASSA T， KANG Y. Metastatic niche functions and therapeutic opportunities［J］. Nat Cell Biol， 2018， 20（8）： 868-877.

YANG Y， SUN M， YAO W， et al. Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib［J］. J Immunother Cancer， 2020， 8（1）：e000317.

YAO W， BA Q， LI X， et al. A natural CCR2 antagonist relieves tumor-associated macrophage-mediated immunosuppression to produce a therapeutic effect for liver cancer［J］. EBioMedicine， 2017， 22： 58-67.

CHEN C， YAO X， XU Y， et al. Dahuang Zhechong Pill suppresses colorectal cancer liver metastasis via ameliorating exosomal CCL2 primed pre-metastatic niche［J］. J Ethnopharmacol， 2019， 238： 111878.

MAO D， FENG L， GONG H. The antitumor and immunomodulatory effect of Yanghe Decoction in breast cancer is related to the modulation of the JAK/STAT signaling pathway［J］. Evid Based Complement Alternat Med， 2018， 2018： 8460526.

XU H， VAN DER JEUGHT K， ZHOU Z， et al. Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation［J］. J Clin Invest， 2021， 131（10）： e146832.

WANG D， WANG F， KONG X， et al. The role of metabolic reprogramming in cancer metastasis and potential mechanism of traditional Chinese medicine intervention［J］. Biomed Pharmacother， 2022， 153： 113376.

LI X， SUN J， XU Q， et al. Oxymatrine inhibits colorectal cancer metastasis via attenuating PKM2-mediated aerobic glycolysis［J］. Cancer Manag Res， 2020， 12： 9503-9513.

SUN X， ZHAO P， LI H， et al. Ginsenoside Rh2 inhibits glycolysis through the STAT3/c-MYC axis in non-small-cell lung cancer［J］. J Oncol， 2021， 2021： 9715154.

ZHENG X， GOU Y， JIANG Z， et al. Icaritin-induced FAM99A affects GLUT1-mediated glycolysis via regulating the JAK2/STAT3 pathway in hepatocellular carcinoma［J］. Front Oncol， 2021， 11： 740557.

ZHU H， XIAO Y， GUO H， et al. The isoflavone puerarin exerts anti-tumor activity in pancreatic ductal adenocarcinoma by suppressing mTOR-mediated glucose metabolism［J］. Aging （Albany NY）， 2021， 13（23）： 25089-25105.

ZHU S， WEI L， LIN G， et al. Metabolic alterations induced by Kudingcha lead to cancer cell apoptosis and metastasis inhibition［J］. Nutr Cancer， 2020， 72（4）： 696-707.

BIAN X， LIU R， MENG Y， et al. Lipid metabolism and cancer［J］. J Exp Med， 2021， 218（1）： e20201606.

WANG Y， GUO D， HE J， et al. Inhibition of fatty acid synthesis arrests colorectal neoplasm growth and metastasis： Anti-cancer therapeutical effects of natural cyclopeptide RA-Ⅻ［J］. Biochem Biophys Res Commun， 2019， 512（4）： 819-824.

ZHANG C J， ZHU N， LONG J， et al. Celastrol induces lipophagy via the LXRα/ABCA1 pathway in clear cell renal cell carcinoma［J］. Acta Pharmacol Sin， 2021， 42（9）： 1472-1485.

HUANG S Y， HUANG G J， WU H C， et al. Ganoderma tsugae inhibits the SREBP-1/AR axis leading to suppression of cell growth and activation of apoptosis in prostate cancer cells［J］. Molecules， 2018， 23（10）： 2539.

GUO S， MA B， JIANG X， et al. Astragalus polysaccharides inhibits tumorigenesis and lipid metabolism through miR-138-5p/SIRT1/SREBP1 pathway in prostate cancer［J］. Front Pharmacol， 2020， 11： 598.

XU M， REN L， FAN J， et al. Berberine inhibits gastric cancer development and progression by regulating the JAK2/STAT3 pathway and downregulating IL-6［J］. Life Sci， 2022， 290： 120266.

YAO M， FAN X， YUAN B， et al. Berberine inhibits NLRP3 inflammasome pathway in human triple-negative breast cancer MDA-MB-231 cell［J］. BMC Complement Altern Med， 2019， 19（1）： 216.

KIM S， YOU D， JEONG Y， et al. Berberine down-regulates IL-8 expression through inhibition of the EGFR/MEK/ERK pathway in triple-negative breast cancer cells［J］. Phytomedicine， 2018， 50： 43-49.

SHAH D， CHALLAGUNDLA N， DAVE V， et al. Berberine mediates tumor cell death by skewing tumor-associated immunosuppressive macrophages to inflammatory macrophages［J］. Phytomedicine， 2021， 99： 153904.

MIZUNO R， KAWADA K， ITATANI Y， et al. The role of tumor-associated neutrophils in colorectal cancer［J］. Int J Mol Sci， 2019， 20（3）： 529.

TAO L， XU M， DAI X， et al. Polypharmacological profiles underlying the antitumor property of salvia miltiorrhiza root （Danshen） interfering with NOX-dependent neutrophil extracellular traps［J］. Oxid Med Cell Longev， 2018， 2018： 4908328.

WANG S， LONG S， DENG Z， et al. Positive role of Chinese herbal medicine in cancer immune regulation［J］. Am J Chin Med， 2020， 48（7）： 1577-1592.

HARRIS A R， PEREZ M J， MUNSON J M. Docetaxel facilitates lymphatic-tumor crosstalk to promote lymphangiogenesis and cancer progression［J］. BMC Cancer， 2018， 18（1）： 718.

Views

下载量

CSCD

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

Research progress in anti⁃tumor clinical efficacy and mechanism of action of Sarcandrae Herba

Research progress in anti⁃tumor regulation of metabolic reprogramming by active components of traditional Chinese herbal medicines

Research progress in monomers of traditional Chinese herbal medicine targeting PI3K/Akt/mTOR signaling pathway to prevent and treat diabetic nephropathy

Mechanism of astragaloside Ⅳ regulating exosome production and secretion and inhibiting metastasis of colorectal cancer

Research progress on mechanism of action of traditional Chinese herbal medicines for treating metabolism associated fatty liver disease

Related Author

No data

Related Institution

Shanghai University of Traditional Chinese Medicine

Sichuan Institute for Translational Chinese Medicine

Department of Oncology I， Shanghai Municipal Hospital of Traditional Chinese Medicine Affiliated to Shanghai University of Traditional Chinese Medicine

Nephrology Department， Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

TCM Institute of Kidney Disease， Shanghai University of Traditional Chinese Medicine

⁰